AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) In 2022: Is This Company Worth Thinking About Investing In?

In the last trading session, 1.46 million shares of the AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) were traded, and its beta was 0.73. Most recently the company’s share price was $0.61, and it changed around $0.05 or 8.00% from the last close, which brings the market valuation of the company to $83.81M. ACRX currently trades at a discount to its 52-week high of $2.94, offering almost -381.97% off that amount. The share price’s 52-week low was $0.46, which indicates that the current value has risen by an impressive 24.59% since then. We note from AcelRx Pharmaceuticals Inc.’s average daily trading volume that its 10-day average is 1.57 million shares, with the 3-month average coming to 1.09 million.

AcelRx Pharmaceuticals Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.70. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ACRX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. AcelRx Pharmaceuticals Inc. is expected to report earnings per share of -$0.07 for the current quarter.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

Instantly ACRX has showed a green trend with a performance of 8.00% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.6079 on Monday, 01/03/22 decreased the stock’s daily price by -0.35%. The company’s shares are currently up 8.00% year-to-date, but still up 15.86% over the last five days. On the other hand, AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) is -1.24% up in the 30-day period. We can see from the shorts that 15.74 million shares have been sold at a short interest cover period of 7.91 day(s).

The consensus price target as assigned by Wall Street analysts is $4.25, which translates to bulls needing to increase their stock price by 85.65% from its current value. Analyst projections state that ACRX is forecast to be at a low of $4.00 and a high of $4.50. In order for the stock price to hit the forecast high, the stock would need to plunge -637.7% from its current level, while the stock would need to crash -555.74% from its current level to reach the projected low.

AcelRx Pharmaceuticals Inc. (ACRX) estimates and forecasts

Moreover, analysts have decided to roll up on their fiscal year 2022 revenue estimates. The rating firms predict that it will gain 30.00% in revenue this quarter, and will report an increase of 30.00% in the next quarter. The year-over-year growth rate is expected to be -5.80%, down from the previous year.

Consensus estimates provided by 2 financial analysts predict the company will bring in an average of $1.9 million in revenue for the current quarter. 2 analysts expect AcelRx Pharmaceuticals Inc. to make $2.22 million in revenue for the quarter ending Dec 2021. The company’s sales for the same quarters a year ago were $1.37 million and $738k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 38.90%. Forecasts for the next quarter put sales growth at 200.80%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 3.00%.

ACRX Dividends

AcelRx Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released around August 09 and August 13.

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.93% of AcelRx Pharmaceuticals Inc. shares, and 34.86% of them are in the hands of institutional investors. The stock currently has a share float of 35.55%. AcelRx Pharmaceuticals Inc. stock is held by 109 institutions, with Blackrock Inc. being the largest institutional investor. By Mar 30, 2021, it held 6.39% of the shares, which is about 7.61 million shares worth $12.94 million.

Shaw D.E. & Co., Inc., with 4.41% or 5.25 million shares worth $8.92 million as of Mar 30, 2021, holds the second largest percentage of outstanding shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Mar 30, 2021. The former held 3.2 million shares worth $5.43 million, making up 2.68% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.26 million shares worth around $3.14 million, which represents about 1.89% of the total shares outstanding.